Treatments for wasting in patients with the acquired immunodeficiency syndrome

New England Journal of Medicine

Volumn 340, Issue 22, 1999, Pages 1740-1750

  Corcoran, Colleen ^a   Grinspoon, Steven ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANTIVIRUS AGENT; DRONABINOL; GLUTAMINE; MEGESTROL ACETATE; NANDROLONE; OXANDROLONE; PENTOXIFYLLINE; PRASTERONE; RECOMBINANT GROWTH HORMONE; TESTOSTERONE; THALIDOMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADRENAL INSUFFICIENCY; ARTHRALGIA; BODY COMPOSITION; BODY FAT; CLINICAL TRIAL; CUSHING DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; EDEMA; EXERCISE; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER DYSFUNCTION; LORDOSIS; META ANALYSIS; MYALGIA; PRIORITY JOURNAL; REVIEW; WASTING SYNDROME; WEIGHT GAIN;

APPETITE STIMULANTS; DIETARY SUPPLEMENTS; EXERCISE; FEMALE; HIV WASTING SYNDROME; HUMAN GROWTH HORMONE; HUMANS; MALE; PARENTERAL NUTRITION; TESTOSTERONE; THALIDOMIDE;

EID: 0033519662     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199906033402207     Document Type: Review

References (78)

1. Mhiri C, Belec L, Di Costanza B, Georges A, Ghcrardi R. The slim disease in African patients with AIDS. Trans R Soc Trop Med Hyg 1992;86: 303-6.
2. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36:Suppl 1: 3S-15S.
3. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985;42: 1255-65.
4. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 1997;82:1332-7. [Erratum, J Clin Endocrinol Metab 1997;82:3360.]
5. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;15:43-8.
6. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunode-ficiency syndrome. Am J Clin Nutr 1992;55:455-60.
7. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995;333: 83-8.
8. Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;76:559-65.
9. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956-62.
10. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988;84: 611-6.
11. Palenicek JP, Graham NMH, He YD, et al. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:366-73.
12. Guenter P, Muurahaninen N, Simons G, et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 1993;6:1130-8.
13. Grinspoon S, Corcoran C, Rosenthal D, et al. Quantitative assessment of cross-sectional muscle area, functional status and muscle strength in men with the AIDS wasting syndrome. J Clin Endocrinol Metab 1999;84:201-6.
14. Balog DL, Epstein ME, Amodio-Groton MI. HIV wasting syndrome: treatment update. Ann Pharmacother 1998;32:446-58.
15. Shabert J, Winslow C, Shabert JK, Lacey J, Wilmore DW. Glutamine/ antioxidant supplementation promotes gain in body cell mass in HIV patients with weight loss. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
16. Rathmacher JA, Clark RH, Feleke G, et al. Effect of amino acid mixture containing β-hydroxy-β-methylbutyrate (HMB) in HIV related wasting. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
17. Von Roenn JH, Armstrong D, Kotler DP, et al. Megcsterol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994;121:393-9.
18. Oster MH, Enders SR, Samuels SJ, et al. Megesterol acetate in patients with AIDS and cachexia. Ann Intern Med 1994;121:400-8.
19. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97
20. Timponc JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 1997;13:305-15.
21. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1998;129:18-26.
22. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. AIDS 1997;11:1347-52.
23. Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998;83:3155-62.
24. Fisher A, Abbatilola M. The effects of oxandrolone on body weight and composition in patients with HIV-associated weight loss. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
25. Gold J, High HA, Li Y, et al. Safety and efficacy of nandrolonc decanoate for the treatment of wasting in patients with HIV infection. AIDS 1996;10:745-52.
26. Spark RF, Sanchez L, Dezube BJ, Libman H. Is dihydrotestosterone the preferred androgen for AIDS wasting? In: Program and abstracts of the 80th Annual Meeting of the Endocrine Society, New Orleans, June 24-27, 1998. Bethesda, Md.: Endocrine Society Press, 1998:109. abstract.
27. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Intern Med 1996;125:873-82.
28. Spence DW, Galantino ML, Mossberg KA, Zimmerman SO. Progressive resistance exercise: effect on muscle function and anthropometry of a select AIDS population, Arch Phys Med Rehabil 1990;71:644-8.
29. Roubenoff R, McDermott A, Wood M, Suri I. Feasibility of increasing lean body mass in HIV-infected adults using progressive resistance training. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
30. Rigsby LW, Dishman RK, Jackson AW, Maclean GS, Raven PB. Effects of exercise training on men seropositive for human immunodeficiency virus-1. Med Sci Sports Exerc 1992;24:6-12.
31. Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997;13:1047-54.
32. Klausner JD, Makomikawesyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogens of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retroviroî 1996;11:247-57.
33. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996;10:1501-7.
34. Dezube BJ, Pardee AB, Chapman B, et al. Pentoxirylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J Acquir Immune Defic. Syndr. 1993;6:787-94.
35. Roubenoff R., Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev 1991;49:163-73.
36. Ott M, Lembcke B, Fischer H, et al. Early changes of body composition in human immunodefficiency virus-infectted patients: tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr 1993;57:15-9.
37. Gibert CL, Muurahainen N, Collins G, et al. Body composition to HIV-infected men and womem in 1996-1997 (CPCRA 038). Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
38. Yarasheski KE, Zachwieja JJ, Gischler J, Crowiey J, Horgan MM, Porederly WG. Increased plasma Gin and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol 1998;275:E577-E583.
39. Fiexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
40. Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deischer H. Mufler MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:239-46.
41. Chiebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritinal stams, gastrointestinal dysfunction and survival in patients with AIDS. Am J Gastroenterol 1989;84:1288-93.
42. Raghavan S, Grant LB, Barisch G, et al. Change in log. HIV RNA & protease inhibitor use associated with weight change in HIV+ men in a national clinical trial. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3,1998. abstract.
43. Schwenk A, Beijenherz A, Kremer G, et al. Impact of protease inhibitor treatment on body composition and prevalence of malnutrition in HIV positive outpatients. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3,1998. abstract.
44. Muurahainen N, Collins G, Wheeler D, et al. Body cell mass (BCM) in HIV-infected (HIV+) males in the community programs for clinical research on AIDS (CPCRA) in 1996-1997. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
45. Volberding PA, Decks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA 1998;279:1343-4.
46. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infectcd patients. AIDS 1998;12:1645-51.
47. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27:68-72.
48. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-5.
49. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
50. Grinspoon S, Corcoran C, Miller K, et al. Determinants of increased energy expenditure in HW-infecred women. Am J Clin Nutr 1998;68:720-5.
51. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:329-37.
52. Melchior J, Chastang C, Gelas P, et al. Efficacy of 2-month total parenteral nutrition in AIDS patients: a controlled randomized prospective trial. AIDS 1996;10:379-84.
53. Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN Jr. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN J Parenter Enterai Nutr 1990;14:434-8
54. Henry K, Rathgaber S, Sullivan C, McCabe K. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med 1992;116:53-4.
55. Padmanabhan S, Rosenberg AS. Cushing's syndrome induced by megestrol acetate in a patient with AIDS. Clin Infect Dis 1998;27:217-8.
56. Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ. Effect of megesterol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 1992;67: 1160-2.
57. Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995; 122:843-5.
58. Grinspoon S. Neuroendocrine manifestations of AIDS. Endocrinologist 1997;7:32-8.
59. Berger D, Muurahainen N, Wittert H, Bucher G, Baker BE, Baker JP. Hypogonadism and wasting in the era of HAART in HIV-infected patients. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
60. Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996; 81:4051-8.
61. Chabon AB, Stenger RJ, Grabstald H. Histopathology of testis in acquired immune deficiency syndrome. Urology 1987;29:658-63.
62. Grinspoon S, Corcoran C, Anderson E, Hubbard J, Basgoz N, Klibanski A. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis 1999:28:634-6.
63. Berger IK, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandtolone sa AIDS-wasting myopathy. AIDS 1996;10:1657-62.
64. Westaby D, Ogle SJ, Paradinas JF, Randell JB, Murray-Lyon IM. Liver damage from long-term methylrestosterone. Lancet 1977;2:262-3.
65. Sinha-Hikim I, Arver S, Beall G, et al. The use of a sensitive equilibrium dialysis method for the measurement of tree testosterone levels in healthy, cycling women and is human immunodeficiency virus-infected women. J Clin Endocrinaol Metab 1998;83:1312-8. [Erratum, J Clin Endocrinol Metab 1998;83:2959.]
66. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency wasting: a pilot study. J Clin Endocrinol Metab 1998;83:2717-25.
67. Forbes GB. Lean body mass-body fat interrelationships in humans. Nutr Rev 1987;45:225-31.
68. Grinspon S, Corcoran C, Stanley R, Katznelson L, Klibanski A. Effects of androgen administration on the growth hormone-insulin-like growth factor azis in men with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 1998;83:4251-6.
69. Baum HBA, Biller BMK, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency: a randomized, place-bo-controlled trial. Ann Intern Med 1996;125:883-90.
70. Ziegler TR, Rombeau JL, Young LS, et al. Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study. J Clin Endocrinol Metab 1992;74:865-73.
71. Wilmore DW, Moylan JA Jr, Bristow BF, Mason AD Jr, Pruitt BA Jr. Anabolic effects of human growth hormone and high caloric feedings following thermal injury. Surg Gynecol Obstet 1974;138:875-84.
72. Krentz AJ, Koster FT, Crist DM, et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993;6:245-51.
73. Lee PD, Pivarnik JM, Bukar JG, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996;81:2968-75. [Erratum, J Clin Endocrinol Metab 1996;81:3696.]
74. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:865-72.
75. Paton N, Newton PJ, Ross HM, et al. Energy balance studies during growth hormone therapy support a metabolic mechanism of action. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
76. Torres R. Treatment of dorsocervical fat pads and truncal adiposity with serostim (recombinant human growth hormone) in patients with AIDSmaintained on HAAKT. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998. abstract.
77. Lahdevirta J, Maury CPJ, Teppo A, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91.
78. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.